A dual MET/AXL small-molecule inhibitor exerts efficacy against gastric carcinoma through killing cancer cells as well as modulating tumor microenvironment.

Zhu, Chenjing; Shi, Huashan; Wu, Min; Wei, Xiawei

Zhu, Chenjing; Shi, Huashan; Wu, Min; Wei, Xiawei.

Afiliação

Zhu C; Laboratory of Aging Research and Cancer Drug Target State Key Laboratory of Biotherapy and Cancer Center National Clinical Research Center for Geriatrics West China Hospital Sichuan University Chengdu Sichuan China.
Shi H; Department of Radiation Oncology Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University Nanjing Jiangsu China.
Wu M; Laboratory of Aging Research and Cancer Drug Target State Key Laboratory of Biotherapy and Cancer Center National Clinical Research Center for Geriatrics West China Hospital Sichuan University Chengdu Sichuan China.
Wei X; Department of Biomedical Sciences School of Medicine and Health Sciences University of North Dakota Grand Forks North Dakota USA.

MedComm (2020) ; 1(1): 103-118, 2020 Jun.

Article em En | MEDLINE | ID: mdl-34766112

Palavras-chave

AXL; LY2801653; MET; gastric cancer; inhibitor

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: MedComm (2020) Ano de publicação: 2020 Tipo de documento: Article